Lexiscan(TM) Rb-82 Myocardial Perfusion PET: A Comparison With Dipyridamole Stress

• Status: Unknown status
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Lexiscan(TM) has ideal properties for Rb-82 PET imaging and the stress response it invokes may offer multiple advantages for the diagnosis of coronary disease and functional abnormalities. The goal of this investigation is to establish quantitative equivalence of Lexiscan(TM) rest/stress Rb-82 PET images to dipyridamole rest/stress images.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cardiovascular Imaging Technologies
• Collaborator: Astellas Pharma US, Inc.
• Treatments: Dipyridamole; Regadenoson

Criteria

Inclusion Criteria:

• BMI <35

• No intervention or change in management between dipyridamole and Lexiscan(TM) PET

Exclusion Criteria:

• BMI >35

• An intervention or change in management between dipyridamole and Lexiscan(TM) PET